Aging was until recently considered to be a decline due to the high accumulation of casual molecular damage that is unpreventable. A hyperfunction theory described aging as the continuation of the growth process spurred on by signal paths like TOR (Target of Rapamycin). Rapamycin has been identified as a useful component in the prevention of diseases as well as treating the aging process in human beings. When offered in the correct doses, rapalogs and rapamycin are used in extending the healthy lifespan of human beings. This theory had been disapproved by anonymous peer-reviewers as well as opponents in the past.
Recent studies have established that a rapamycin analog, Evirolimus (RAD001), generally improves the immunity of aging persons. This news made headlines as researchers are on the brink of finding a drug that will be capable of delaying the effects associated with aging and generally improve the health of adults in advanced ages. Nir Barzilai summarizes that this new discovery has set the stage for finding a drug that will improve every pending thing about the aging process. At the moment, both human beings and animals die as a result of diseases related to age, due to the aging process. When the aging process is slowed down, calorie restriction and rapamycin will be capable of delaying all age-related diseases like cancer. In the study of anti-oxidants and free radicals, gerontologists stumbled upon metformin and rapamycin, which are anti-aging drugs. Intensive studies on rapamycin and other anti-aging drugs are ongoing in order to find conclusive results on their anti-aging properties.
Understanding Oncology Via Mikhail Blagosklonny
Mikhail Blagosklonny is a renowned scientist who majors in the studies of both cancer and the aging process. He is an Oncology professor at the Roswell Park Cancer Institute. He holds an MD (Internal Medicine) as well as an Experimental Medicine and Cardiology Ph.D. from the First Pavlov State Medical University, St. Petersburg. Dr. Blagosklonny is a great professor who is interested in the areas of cancer, anti-aging drugs as well as targeted cancer therapies in nature in order to prevent healthy cells from harm.Mikhail Blagosklonny, Oncotarget’s editor-in-chief, came up with a hypothesis that touches on TOR signaling playing a major role in the aging process as well as cancer. He proposes the use of rapamycin, a drug that is popularly used in cancer treatment. Dr. Blagosklonny suggested that there is a possible breakthrough treatment that can treat lie extension. Mikhail Blagosklonny is held in high regard as he is a passionate rapamycin advocate. His research touches on molecular and cellular biology in his clinical investigations. His investigations mainly include drug resistance in normal cells, ontogenesis, signal transduction, tumor suppressors, apoptosis, mitosis, anticancer therapeutics and cell cycle.
Mikhail Blagosklonny and Oncology
Dr. Blagosklonny is widely known for his huge passion in the oncology field. He holds a strong belief that both cancer and aging processes can be controlled. He suggested the use of rapamycin in cancer treatment as he believes that it can cure cancer. His huge passion and contributions in this field have made him become one of the top Oncology researchers on the planet.